SYRE completes equity offering; option exercised in full

Rhea-AI Filing Summary

Spyre Therapeutics (SYRE) completed an underwritten public offering of common stock. The company sold 14,864,865 shares at $18.50 per share and granted a 30-day option for up to 2,229,729 additional shares, which the underwriters exercised in full on October 14, 2025. The offering closed on October 15, 2025.

Gross proceeds were approximately $316.2 million before underwriting discounts, commissions, and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, as well as for working capital and general corporate purposes. The transaction was conducted off an effective Form S-3 shelf, with Jefferies, TD Securities (USA), Leerink Partners, and Stifel as representatives of the underwriters.

Insights

Equity Capital Markets Analyst

Primary equity raise brings in cash; share issuance completed.

Spyre Therapeutics executed a firm commitment offering at $18.50 per share, selling 14,864,865 shares, with the underwriters’ 30-day option for up to 2,229,729 additional shares exercised in full on October 14, 2025. The deal closed on October 15, 2025.

The transaction delivered gross proceeds of $316.2 million to the company before fees. As a primary issuance, cash flows to the issuer, while new shares increase the public float. Use of proceeds targets IBD and rheumatic disease programs, spanning preclinical, clinical, manufacturing, and Phase 3 readiness.

Key dependencies include execution of planned studies and manufacturing scale-up funded by the raise. Future disclosures may specify trial starts and spending cadence tied to this capital; those details are not provided in the excerpt.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM Learn about SEC filing dates

FAQ

What did Spyre Therapeutics (SYRE) announce in this filing?

The company completed an underwritten public offering of common stock that closed on October 15, 2025.

How many SYRE shares were sold and at what price?

Spyre sold 14,864,865 shares at a public offering price of $18.50 per share.

Was the underwriters’ option exercised?

Yes. The underwriters exercised in full their 30-day option to purchase up to 2,229,729 additional shares on October 14, 2025.

How much did Spyre Therapeutics raise in gross proceeds?

Gross proceeds were approximately $316.2 million before deducting fees and expenses.

What will SYRE use the proceeds for?

To advance programs in inflammatory bowel disease and rheumatic diseases, including preclinical studies, clinical trials, manufacturing, Phase 3 readiness, and for working capital and general corporate purposes.

Which banks led the offering for SYRE?

Jefferies, TD Securities (USA), Leerink Partners, and Stifel served as representatives of the underwriters.

Under what registration was the SYRE offering made?

The offering was made under the company’s Form S-3 shelf (File No. 333-285341), effective March 7, 2025.

false 0001636282 0001636282 2025-10-13 2025-10-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2025

SPYRE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-37722		46-4312787
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

221 Crescent Street
Building 23
Suite 105
Waltham, MA		02453
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 651-5940

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share		SYRE		The Nasdaq Stock Market LLC
				(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On October 13, 2025, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,864,865 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $18.50 per share. In addition, the Company granted the Underwriters a 30-day option (the “Option”) to purchase up to an additional 2,229,729 shares of Common Stock on the same terms and conditions as the Common Stock sold in the Offering, which the Underwriters exercised in full on October 14, 2025. The Offering closed on October 15, 2025.

The gross proceeds to the Company from the Offering were approximately $316.2 million, before deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds of the offering to continue to advance its programs in inflammatory bowel disease and rheumatic diseases, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities in support of its antibody programs, as well as for working capital and general corporate purposes.

The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-285341), which was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 27, 2025, and became effective on March 7, 2025. A final prospectus supplement dated October 13, 2025, relating to and describing the terms of the Offering was filed with the SEC on October 14, 2025.

The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions. In the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the Underwriters may be required to make because of such liabilities.

A copy of the Underwriting Agreement is filed as Exhibit 1.1 and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

An opinion dated October 15, 2025 relating to the legality of the issuance and sale of the Common Stock in the Offering is filed herewith as Exhibit 5.1.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
1.1		Underwriting Agreement, by and among the Company and Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, dated as of October 13, 2025
5.1		Opinion of Ropes & Gray LLP
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						SPYRE THERAPEUTICS, INC.
Date: October 15, 2025				By:		/s/ Cameron Turtle
						Cameron Turtle Chief Executive Officer